SCHEMBL5376799

SCHEMBL5376799

Cc1ccc(S(=O)(=O)Nc2ccc(/C=C/c3ccccc3)cc2)cc1C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.66
PKM P14618 1/20 0.53
HDAC1 Q13547 11/20 0.51
HDAC8 Q9BY41 9/20 0.51
HDAC4 P56524 9/20 0.51
HDAC3 O15379 7/20 0.51
HDAC7 Q8WUI4 7/20 0.51
HDAC2 Q92769 7/20 0.51
HDAC10 Q969S8 7/20 0.51
HDAC11 Q96DB2 7/20 0.51
HDAC6 Q9UBN7 7/20 0.51
HDAC9 Q9UKV0 7/20 0.51
HDAC5 Q9UQL6 7/20 0.51
LMNA P02545 1/20 0.51
BRD4 O60885 1/20 0.50
ESR1 P03372 1/20 0.50
PTGS1 P23219 1/20 0.50
PDE4A P27815 1/20 0.50
PIK3CA P42336 1/20 0.50
HTR6 P50406 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376802 1.00 POLB (0.66) POLBPKMHDAC1HDAC8HDAC4
SCHEMBL12598081 0.88 POLB (0.73) POLBLMNAMAPK1SMN1; SMN2
SCHEMBL5376772 0.85 KMT2A (0.62) POLBHDAC1HDAC8HDAC4HDAC3
SCHEMBL5376767 0.85 KMT2A (0.62) POLBHDAC1HDAC8HDAC4HDAC3
SCHEMBL12597593 0.82 POLB (0.72) POLBLMNASMN1; SMN2
SCHEMBL5501882 0.81 POLB (0.70) POLBMAPK1SMN1; SMN2
SCHEMBL5376605 0.80 POLB (0.65) POLBPKMHDAC1HDAC8HDAC4
SCHEMBL30515752 0.80 POLB (1.00) POLBPKMLMNABRD4MAPK1
SCHEMBL3061848 0.79 CA12 (0.61) POLBLMNAMAPK1SMN1; SMN2
SCHEMBL7322058 0.79 MEN1 (0.75) POLBPKMHDAC1HDAC8HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD POLB 1807/4885PKM 861/4885HDAC1 416/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD POLB 2006/4885PKM 859/4885HDAC1 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.